amrecibart

{
  "id": "MLC-T-ONC-010048",
  "term": "amrecibart",
  "field": "Oncology and biomedicine",
  "definition": "An anti-factor XI (FXI) antibody, with potential anti-thrombotic activity. Upon administration, amrecibart targets and binds to the apple 2 (A2) domain of FXI and activated FXI (FXIa), thereby preventing the intrinsic pathway-triggered FXI activation. This prolongs the activated partial thromboplastin time (aPTT) and reduces platelet and fibrin accumulation. This results in the inhibition of contact activation-initiated blood coagulation and prevents thrombus formation. FXI contributes to thrombotic disease while playing a limited role in normal hemostasis. Activation of FXI is essential for thrombus growth and stabilization.",
  "synonyms": [
    "anti-factor XI antibody REGN9933",
    "anti-factor XI monoclonal antibody REGN9933",
    "anti-FXI monoclonal antibody REGN9933"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/amrecibart/"
}